MedPath

"MiniMed 640G System" User Evaluation With the Question of Reducing the Rate of Hypoglycemia

Completed
Conditions
Type 1 Diabetes
Registration Number
NCT02325193
Lead Sponsor
Kinderkrankenhaus auf der Bult
Brief Summary

The Minimed®640G system (MM640G) consists of a combination of insulin and glucose sensor for continuous glucose monitoring (CGM). Here, the glucose sensor transmits not only the continuous glucose data on the display of insulin pump but, in the case of hypoglycemia also interrupt their insulin delivery of pump. In the currently available system Paradigm®VEO, the interruption takes place at a settled threshold level. In difference in the new system MM640G the shutdown algorithm can already be proactive and help avoid hypoglycemia completely. The so called PLGM algorithm (predictive low glucose management) should be tested in the user evaluation. The main objective is to answer the question of reducing the rate of hypoglycemia by application of the new PLGM algorithm.

Included are a total of 24 patients, aged 1-21 years, in three pediatric diabetes centers.

Detailed Description

In the first phase of two weeks, the sensor-augmented pump therapy (SaP) is carried out without these interruption PLGM algorithm. In a second phase for 6 weeks, the PLGM function is set. Both phases are compared in terms of the rate of hypoglycemia, the time spent and the area under the curve (AUC) glucose range (values \<70 mg / dl (3.9 mmol / l)).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  • type 1 diabetes, diagnosed since 12 month at least
  • continuous subcutaneous insulin infusion (CSII) since 3 month at least
  • stable outcome since 3 month at least
  • willingness of patients/ parents to wear a glucose sensor for 2 month
  • willingness of patients/ parents to use the Minimed®640G system
  • willingness of patients/ parents to complete a diary
  • willingness of patients/ parents to comply the requirements of the study protocol
Exclusion Criteria
  • longer absence of the patients (not able to attend the study visits)
  • subject with allergy of sensor or specific sensor components
  • communication problems
  • significant history of eating disorder, anorexia, bulimia
  • pregnancy
  • significant history of drug abuse or/ and alcoholism
  • patient do not want to attend the trial
  • missing informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
average AUC/day in hypoglycaemic range < 70mg/dl (3,9mmo/l)6 weeks
Secondary Outcome Measures
NameTimeMethod
Number of PLGM activities6 weeks

Trial Locations

Locations (1)

Kinder - und Jugendkrankenhaus AUF DER BULT

🇩🇪

Hannover, Germany

© Copyright 2025. All Rights Reserved by MedPath